Michael K. Schultz, PhD
July 10, 2013
Michael K. Schultz, PhD is a founding member and Chief Science Officer of Viewpoint Molecular Targeting, Inc. Dr. Schultz is concurrently an Associate Professor of Radiology and Free Radical and Radiation Biology at the University of Iowa. Dr. Schultz has held continuous funding for over a decade from the National Institutes of Health (NIH)/ National Cancer Institute (NCI) and has published over 75 peer-reviewed journal articles, book chapters, and invited publications. Dr. Schultz is a Principal Investigator on a currently funded NIH Research Project Grant (R01) to conduct a Phase 1 clinical imaging and therapy trial of VMT-a-NET at the University of Iowa and has served as Co-Investigator (with acting CEO and CMO Frances Johnson, MD of Viewpoint) on over $6M of NCI funded Small Business Innovation Research grant projects. In addition to his role on the current R01 ($3.5M), Dr. Schultz is a Project Leader for the University of Iowa NIH sponsored Specialized Project of Research Excellence in Neuroendocrine Tumors (a $10M, 5-year grant) and has been the primary architect, Principal Investigator, or Co-Investigator on over $20M in total of grants from the NIH, Nuclear Regulatory Commission, Department of Energy, Department of Homeland Security, and industry funded research projects. Dr. Schultz has 5 years of experience in product management in radiation detectors, electronics, and software (PerkinElmer/Ametec); 17 years experience in radiopharmaceutical CMC/IND approvals; and served as a consultant to Algeta ASA (acquired by Bayer) on the CMC for the first alpha-particle targeted therapy approved in the United States (Xofigo).